Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

How switching from brand name drugs to generics is sometimes absurd

Paul Sax, MD
Meds
June 16, 2011
Share
Tweet
Share

I had an interesting exchange with one of our nurses recently about a long-term patient of ours.

The e-mails went something like this:

Got a fax from —-’s insurance that his Lipitor won’t be covered anymore.  They will cover simvastatin, lovastatin, and pravastatin.  Let me know what you want to do.
Charlie

He’s on darunavir, and all three of those statins are contraindicated because of drug-drug interactions. Rosuvastatin?
Paul

Checked with them — rosuvastatin needs prior approval, and will cost him a lot more, but less than Lipitor. I’ll get the paperwork ready.
Charlie

An hour or so passes, and then this:

What dose rosuvastatin?
Charlie

5 mg daily, thanks.
Paul

Another hour, and then:

Just heard from them — after all the fuss, they approved the Lipitor after all.  Seems they just wanted to waste our time.
Charlie

Hysterical.

Look, I get it that generics are usually more cost-effective than branded drugs.  And I understand that health care costs are wildly out of control, and one way of controlling costs is to use generics whenever they are safe and effective, which is most of the time.

But think about the absurdity of the above case.

  1. The insurance company is paying for this man’s antiretroviral therapy, so they must know he’s on darunavir.
  2. They nonetheless are suggesting he switch to a contraindicated generic statin drug.
  3. They initially refuse to continue covering a drug that is working well and that the patient has been tolerating for years, but grudgingly will cover a slightly cheaper alternative.
  4. They set up barriers to jump over and tunnels to crawl through (the “prior approval” paperwork) even though there’s sound evidence to back up the requested brand-name treatments.
  5. After the obstacle course is navigated successfully by our experienced nurse, they relent and say that they’ll cover the original prescription after all.

And here’s the best part:  The exact same thing happened last year with this patient — with the same insurance company!

Reminds me of the classic Monty Python “Cheese Shop” sketch, where the customer (John Cleese) methodically asks cheese shop guy (Michael Palin) for dozens of different cheeses — all of them unavailable. When Cleese asks at the end if they have “any cheese at all,” here’s the response:

No, sir, not a scrap. I was deliberately wasting your time, sir.

ADVERTISEMENT

Paul Sax is the Clinical Director of Infectious Diseases at Brigham and Women’s Hospital. His blog HIV and ID Observations, is part of Journal Watch, where he is Editor of Journal Watch AIDS Clinical Care.

Submit a guest post and be heard on social media’s leading physician voice.

Prev

The accidental genius of homeopathy thrives

June 16, 2011 Kevin 37
…
Next

Docs vs Glocks, and the slippery slope of HB 155

June 16, 2011 Kevin 39
…

Tagged as: Medications, Specialist

Post navigation

< Previous Post
The accidental genius of homeopathy thrives
Next Post >
Docs vs Glocks, and the slippery slope of HB 155

ADVERTISEMENT

More by Paul Sax, MD

  • An infectious disease doctor answers your COVID-19 and coronavirus questions

    Paul Sax, MD
  • When should physicians read the House of God?

    Paul Sax, MD
  • Should we write that patients are “pleasant” in medical notes?

    Paul Sax, MD

More in Meds

  • The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients

    Adwait Chafale
  • A psychiatrist’s 20-year journey with ketamine

    Muhamad Aly Rifai, MD
  • How drug companies profit by inventing diseases

    Martha Rosenberg
  • Every medication error is a system failure, not a personal flaw

    Muhammad Abdullah Khan
  • Why kratom addiction is the next public health crisis

    Muhamad Aly Rifai, MD
  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Most Popular

  • Past Week

    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • IMGs are the future of U.S. primary care

      Adam Brandon Bondoc, MD | Physician
    • How I learned to love my unique name as a doctor

      Zoran Naumovski, MD | Physician
    • From nurse practitioner to leader in quality improvement [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • Love, birds, and fries: a story of innocence and connection

      Dr. Damane Zehra | Physician
  • Recent Posts

    • How I learned to love my unique name as a doctor

      Zoran Naumovski, MD | Physician
    • My first week on night float as a medical student

      Amish Jain | Education
    • What Beauty and the Beast taught me about risk

      Jayson Greenberg, MD | Physician
    • Creating safe, authentic group experiences

      Diane W. Shannon, MD, MPH | Physician
    • The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients

      Adwait Chafale | Meds
    • Healing from medical training by learning to trust your body again [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 12 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • IMGs are the future of U.S. primary care

      Adam Brandon Bondoc, MD | Physician
    • How I learned to love my unique name as a doctor

      Zoran Naumovski, MD | Physician
    • From nurse practitioner to leader in quality improvement [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • Love, birds, and fries: a story of innocence and connection

      Dr. Damane Zehra | Physician
  • Recent Posts

    • How I learned to love my unique name as a doctor

      Zoran Naumovski, MD | Physician
    • My first week on night float as a medical student

      Amish Jain | Education
    • What Beauty and the Beast taught me about risk

      Jayson Greenberg, MD | Physician
    • Creating safe, authentic group experiences

      Diane W. Shannon, MD, MPH | Physician
    • The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients

      Adwait Chafale | Meds
    • Healing from medical training by learning to trust your body again [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

How switching from brand name drugs to generics is sometimes absurd
12 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...